OriCiro Genomics

Tokyo, Japan

OriCiro Genomics develops and commercializes cell-free synthesis and amplification technologies of large DNA molecules.

Jun 2022

Series B

Biotechnology Genetics Health Care Life Science

Top Investors

UTEC - The University of Tokyo Edge Capital Partners ITOCHU Technology Ventures Japan Finance Corporation Asahi Kasei

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about OriCiro Genomics

Who are OriCiro Genomics's investors?

OriCiro Genomics's investors include UTEC - The University of Tokyo Edge Capital Partners, ITOCHU Technology Ventures, Japan Finance Corporation, Asahi Kasei.

Where is OriCiro Genomics headquartered?

OriCiro Genomics is headquartered in Tokyo, Japan.

What does OriCiro Genomics do?

OriCiro Genomics develops and commercializes cell-free synthesis and amplification technologies of large DNA molecules.

What stage is OriCiro Genomics at?

OriCiro Genomics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 5, 2022.

MLA

"OriCiro Genomics — Funding & Investors." VCBacked, June 5, 2022, https://www.vcbacked.co/company/oriciro-genomics. Accessed July 2, 2026.

APA

VCBacked. (2022). OriCiro Genomics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/oriciro-genomics

Wikipedia (cite web)

{{cite web |title=OriCiro Genomics — Funding & Investors |url=https://www.vcbacked.co/company/oriciro-genomics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 5, 2022.